Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care

ANTHOLOGY aims to broaden understanding of the contemporary epidemiology of ATTR amyloidosis, identify opportunities to accelerate diagnosis, and assess real-world comparative effectiveness of treatments. This knowledge will be used to define world-class patient care, improve treatment outcomes and HRQoL, inform updates to clinical practice guidelines and treatment pathways, and transform ATTR amyloidosis management through evidence aimed at improving the quality of the current standard of care TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT06355934 (OverTTuRe) and NCT06465810 (MaesTTRo).

Authors

Institutions

Publication Details

Journal
Cardiology and Therapy
Published
2025-03-19
DOI
https://doi.org/10.1007/s40119-025-00402-y
Citations
3
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
2.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care

Zhuang Tian, J. G. Smith, Eric Wittbrodt, Krister Järbrink et al.
3 citations
Cardiology and Therapy
Amyloidosis: Diagnosis, Treatment, Outcomes
2.42
article

Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care

Zhuang Tian, J. G. Smith, Eric Wittbrodt, Krister Järbrink, Mia A. Papas, Margot K. Davis, Katrin Hahn, Julian D. Gillmore, Isabel M. Conceição, Christina Pao, Martha Grogan
article en
3 citations

Abstract

ANTHOLOGY aims to broaden understanding of the contemporary epidemiology of ATTR amyloidosis, identify opportunities to accelerate diagnosis, and assess real-world comparative effectiveness of treatments. This knowledge will be used to define world-class patient care, improve treatment outcomes and HRQoL, inform updates to clinical practice guidelines and treatment pathways, and transform ATTR amyloidosis management through evidence aimed at improving the quality of the current standard of care TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT06355934 (OverTTuRe) and NCT06465810 (MaesTTRo).

Cardiology and TherapyVol. 14(3)
University of Lisbon (PT), University of British Columbia (CA), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Sahlgrenska University Hospital (SE), The Royal Free Hospital (GB), Peking Union Medical College Hospital (CN), Mayo Clinic in Arizona (US), AstraZeneca (Sweden) (SE), Hospital de Santa Maria (PT), AstraZeneca (United States) (US), University College London (GB), Charité - Universitätsmedizin Berlin (DE), University of Gothenburg (SE)
AstraZeneca
Gender equality
Openalex Percentile: Top 12%
Amyloidosis: Diagnosis, Treatment, Outcomes
2.42
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.